锦波生物(832982) - 2024 Q4 - 年度业绩预告

Financial Forecast - The company forecasts a net profit of approximately CNY 71.9 million to CNY 73.7 million for the year 2024, representing an increase of 139.83% to 145.83% compared to the previous year's net profit of CNY 29.98 million[5]. - The performance forecast is based on preliminary calculations and has not yet been audited by an accounting firm, highlighting the need for investors to exercise caution[2][8]. Innovation and Research Commitment - The company emphasizes its commitment to original innovation and continuous research in structural materials and major infectious diseases, leading to sustainable revenue growth[6][7].